Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
Open Access
- 5 May 2022
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 15 (2) , 494-498
Abstract
Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient’s performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.Keywords
This publication has 4 references indexed in Scilit:
- Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsNew England Journal of Medicine, 2020
- Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?Cancer Treatment Reviews, 2017
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the InevitableLung Cancer, 2017